Lantheus licensed exclusive worldwide rights (excluding certain territories) to PNT2003 from POINT Biopharma Global, Inc. in December 2022. To read the press release announcing that licensing ...

Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract ...

New indication authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) expands access to lutetium177 ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) ...

Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...

SHINE's new large-scale medical isotope production facility. Submitted photo. Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and ...

The MarketWatch News Department was not involved in the creation of this content. Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, ...

Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...

Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177 Lu) Companies enter into an additional manufacturing and supply agreement for ...

TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations. This is an ASCO Meeting Abstract from the ...

@2024 - All Right Reserved.

Lutetium-177 vipivotide tetraxetan 1 is a widely approved breakthrough drug for metastatic prostate cancer. It is manufactured and distributed by Novartis (Basel, Switzerland) under the trade name ...